atezolizumab + docetaxel

Atezolizumab + docetaxel is a combination regimen used primarily in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) and being studied in other advanced cancers. **Atezolizumab** is a monoclonal antibody that inhibits the immune checkpoint protein PD-L1 (programmed death-ligand 1), enhancing anti-tumor immune response by allowing T cells to recognize and eliminate cancer cells. **Docetaxel** is a cytotoxic small molecule chemotherapy agent that stabilizes microtubules, thereby inhibiting cell division and inducing apoptosis in proliferative tumor cells. This combination targets both tumor cell proliferation (via docetaxel) and the immune microenvironment (via atezolizumab checkpoint inhibition), aiming to provide synergistic anti-cancer effects in patients who have progressed following platinum-based chemotherapy[1][3]. The combination is under clinical investigation and occasionally used as follow-up therapy, with its primary indications including NSCLC. Studies are also evaluating its benefit in squamous cell carcinoma of the anus and other solid tumors.

Other names

atezolizumab and docetaxel